Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - ELVN

Published August 18, 2026

$59.4

-0.23%

Event

Read full article on benzinga.com →

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Stock Price

$59.58

Price Change

+0.04%

Exchange Mix — Recent ELVN Events

NASDAQ

100%

NYSE

AMEX

OTC